Home

A method to precisely control the amount of pressure applied by the fluid flow from the lithotripsy device with a stopcock. Background:
In percutaneous nephrolithotomy, the urologist inserts a needle into the kidney, dilating a tract into which a sheath is inserted. Fluid irrigation and lithotripsy are then used to break up and retrieve kidney stones into a vial, via the sheath.The devices used for this purpose have channels through which suction is applied from an external source to remove the stones; however, they do not have a method for modulating that suction. Instead, someone in the OR has to clamp or bend the suction tubing in order to slow or release the flow.

This is awkward, imprecise and frustrating; too much suction can lead to loss of visualization and air bubbles inside the body; too little suction can also reduce visualization due to the buildup of particles and/or stone fragments in the tubing. These particles and/or fragments sometimes stick to the inside of the suction tubing; they are difficult to remove and this gums up the works, limiting the effectiveness of the suction device.Technology Overview:  
A SUNY Upstate Medical University team has created a method for reducing pressure buildup in the pelvis during endoscopic procedures. First, the researchers determined the optimal shape of a ureteroscope for reducing intrapelvic pressure. Next, they found that by offsetting the endoscope to the side of the access sheath, which contains the endoscope, they could substantially improve fluid outflow and reduce pressure. Finally, the team determined that this displacement could be achieved by adding small, radially emanating projections within the working channel of the scope. They concluded that any endoscope or catheter could be adapted with these projections and that the methods could also be used with bronchoscopes to reduce the disruption in air flow.  https://suny.technologypublisher.com/files/sites/adobestock_4398441972.jpegAdvantages:

• Makes endoscopy safer for patients.
• Reduces pressure that can cause infection, injury, and pain.
• Modifications can be used to adapt any endoscope or catheter

 Applications:

• Reduces pressure buildup during endoscopic procedures.

 Intellectual Property Summary:

• Patent application submitted
• Provisional patent

Licensing Status:
This technology is available for licensing.
 

Antibody against Endoplasmic reticulum lipid raft associated 1 (Erlin-1; also known as anti-KE04 and anti-SPFH)   Background:  Erlin1 (endoplasmic reticulum lipid raft associated 1) is part of a protein complex that mediates degradation of inositol 1,4,5-trisphosphate receptors in the endoplasmic reticulum. The encoded protein also binds cholesterol and regulates the SREBP signaling pathway, which promotes cellular cholesterol homeostasis. Defects in this gene have been associated with spastic paraplegia 62. https://www.ncbi.nlm.nih.gov/gene/10613   Technology Overview:  

• Polyclonal, affinity-purified
• Immunogen: amino acids 332-346 of rat Erlin-1

  https://suny.technologypublisher.com/files/sites/2011-110.png Applications:   

• Western blot 
• ELISA 
• Immunoprecipitation
• Immunofluorescence assays  

 

Novel luciferase reporter provides optimal performance in high-throughput screens of G-protein-coupled agonist binding.Background: G-protein-coupled receptors (GPCRs) constitute the largest class of cell surface receptors. GPCR genes account for 5% of the human genome. GPCRs also represent the largest and among the most efficacious classes of therapeutic targets for diseases including cardiovascular disease, cancer, and asthma. Technology Overview:  The novel cyclic adenosine monophosphate (cAMP)-responsive luciferase  reporter exhibits optimal performance in high-throughput screens of agonist binding at GPCRs. This reporter exhibits substantially reduced basal activity, a feature that is likely to be of particular importance when performing high-throughput screens in which false-positive hits are to be avoided. Compared to other reporters, the present construct affords a much wider dynamic range of activation (>340 fold-stimulation) upon exposure to GPCR agonists with cAMP signaling properties. https://suny.technologypublisher.com/files/sites/2009-110.jpghttps://www.pexels.com/photo/scientist-in-laboratory-3735769/ Advantages:  

• Significantly reduced basal luciferase activity inherent to similar reporters.
• Wide dynamic range of activation upon exposure to agonist.

   Applications:  

• Research tool
• Drug candidate high-throughput screening

 

A nanocarrier platform for Amphotericin B that improves efficacy and reduces cost, while decreasing toxicity. Background:
Systemic fungal infections are an increasingly prevalent health problem. The hydrophobic polyene antibiotic Amphotericin B (AmB) is the drug of choice for these life-threatening invasive fungal infections. Unfortunately, it produces dose-limiting side effects such as nephrotoxicity. For example, Fungizone® is a conventional sodium deoxycholate micellar formulation of AmB that exhibits high nephrotoxicity and infusion-related reactions. Clinically approved liposomal formulations of AmB, such as AmBisome, reduces AmB toxicity, but do not offer better clinical efficacy. Numerous nanoformulations have been developed for AmB delivery to improve the efficacy and reduce toxicity and cost. However, current options cannot enable the fine-tuning of AmB aggregation in a nanocarrier, which is directly associated with the efficacy and toxicity of AmB formulation for clinical translation.Technology Overview:  
This technology is a PEGylated linear-dendritic telodendrimer (TD) nanocarrier platform for customized nanocarrier design. Different hydrophobic groups can be freely introduced on the dendritic periphery of TD to fine-tune the hydrophobicity and flexibility of the core structure of micelle to control AmB molecular aggregation. The AmB aggregation status in this nanoformulation has a positive correlation with the haemolytic activity and a reverse correlation with antifungal activity. The optimized nanoformulation, with the highest monomeric AmB, significantly improves the antifungal activities and reduces the toxicity both in vitro and in vivo in comparison to Fungizone and AmBisome. This offers significant promise for clinical translation with increased therapeutic window and reduced cost in comparison to the lipid formulations (e.g. AmBisome). https://suny.technologypublisher.com/files/sites/adobestock_436803475_(002).jpegAdvantages:  

• Decreases toxicity compared to other AmB options.
• Increases clinical efficacy.
• Reduces cost.

 Applications:  
The primary application for this technology is the development of AmB therapeutics for the treatment of fungal infections.  Intellectual Property Summary:
Provisional Patent Application 63/441,993 filed on 1/30/2023
Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.Licensing Potential:
This technology would be of interest to anyone involved in the development of treatments for fungal infections based on AmB, including:

• Pharmaceutical companies
• Medical research centers
• Hospitals
• Universities